Person: ÇELİK, BURAK
5 results
Search Results
Now showing 1 - 5 of 5
Publication Open Access Design, optimization and characterization of coenzyme Q10-and D-panthenyl triacetate-loaded liposomes(2017-01-01) Celik, BURAK; Sagiroglu, ALİ; Ozdemir, Samet; ÇELİK, BURAK; ASRAM SAĞIROĞLU, ALİCoenzyme Q10 (CoQ10) is a lipid-soluble molecule found naturally in many eukaryotic cells and is essential for electron transport chain and energy generation in mitochondria. D-Panthenyl triacetate (PTA) is an oil-soluble derivative of D-panthenol, which is essential for coenzyme A synthesis in the epithelium. Liposomal formulations that encapsulate both ingredients were prepared and optimized by applying response surface methodology for increased stability and skin penetration. The optimum formulation comprised 4.17 mg CoQ10, 4.22 mg PTA and 13.95 mg cholesterol per 100 mg of soy phosphatidylcholine. The encapsulation efficiency of the optimized formulation for CoQ10 and PTA was found to be 90.89%±3.61% and 87.84%±4.61%, respectively. Narrow size distribution was achieved with an average size of 161.6±3.6 nm, while a spherical and uniform shape was confirmed via scanning electron microscopy and transmission electron microscopy images. Cumulative release of 90.93% for PTA and 24.41% for CoQ10 was achieved after 24 hours of in vitro release study in sink conditions. Physical stability tests indicated that the optimized liposomes were suitable for storage at 4°C for at least 60 days. The results suggest that the optimized liposomal formulation would be a promising delivery system for both ingredients in various topical applications. Keywords: coenzyme Q10, D-panthenyl triacetate, liposomes, response surface methodology, stabilityPublication Metadata only Therapeutic Potential of Drug Delivery by Means of Lipid Nanoparticles: Reality or Illusion?(2017-01-01) Uner, Melike; Damgali, Sukran; Ozdemir, Samet; Celik, BURAK; ÇELİK, BURAKBackground: Solid lipid nanoparticles (SLN) are colloidal drug carrier systems that contribute several properties required from a sophisticated drug delivery system for increasing drug bioavailability and providing effective therapy. Many advantages of SLN have been reported over traditional dosage forms and their colloidal counterparts since the early 1990s. They were optimized for oral drug delivery for the first time. The first SLN formulations were produced by reducing particle size of solid lipid microparticles by spray congealing technique in the late 1980s. Then, studies have been continued investigating for their different administration routes else including parenteral, transdermal, ocular, nasal, respiratory etc.Publication Metadata only Optimization of piribedil mucoadhesive tablets for efficient therapy of Parkinson-s disease: physical characterization and ex vivo drug permeation through buccal mucosa(2017-01-01) Celik, BURAK; Ozdemir, Samet; Demirkoz, Asli Barla; Uner, Melike; ÇELİK, BURAKObjective: The aim of this study was optimization of buccal piribedil (PR) mucoadhesive tablets to improve its low bioavailability and provide controlled release for the treatment of Parkinson-s disease.Publication Metadata only Eplerenone nanoemulsions for treatment of hypertension. Part II: Physical stability assessment and in vivo study(2018-06-01T00:00:00Z) Ozdemir, Samet; Celik, BURAK; Sumer, Engin; Acar, Ebru Turkoz; Uner, Melike; ÇELİK, BURAKThe aim of the present complimentary study was to investigate physical stability of eplerenone (EP) loaded nanoemulsions and to evaluate their pharmacokinetic profiles after subcutaneous application to Sprague Dawley rats. Nanoemulsions were prepared by using high shear homogenization and ultrasonication techniques. All formulations were having 0.1% EP. They were obtained in 150.6 nm-205.8 nm size range. Physical stability of nanoemulsions was monitored storing them at different thermal conditions for 120 days. Droplet size was confirmed to be affected by storage temperature when it slightly changed at 4 +/- 2 degrees C and 25 +/- 2 degrees C. 40 +/- 2 degrees C was found not to be suitable as a storage condition in general. Pharmacokinetic study on physically stable formulations demonstrated that subcutaneously applied eplerenone solution showed that AUC(0)->infinity and C-max were 1.62 and 2.05 folds higher than eplerenone solution after oral administration. Additionally, AUC(0)->infinity and C-max were significantly increased in the case of nanoemulsions prepared with Brij (R) 35 and Tween (R) 80. Relative bioavailability of the drug was found to be remarkably increased after administration of formulations stabilized with Tween (R) 80. Results suggested that eplerenone loaded nanoemulsions may provide an alternative application way for efficient management of hypertension attacks.Publication Metadata only Eplerenone nanoemulsions for treatment of hypertension. Part I: Experimental design for optimization of formulations and physical characterization(2018-06-01T00:00:00Z) Ozdemir, Samet; Celik, BURAK; Acar, Ebru Turkoz; Duman, Gulengul; Uner, Melike; ÇELİK, BURAKNanoemulsions of eplerenone (EP) were designed with the aim of improving its bioavailability for an effective antihypertensive therapy. Nanoemulsions were prepared by high shear homogenization and ultrasonication methods. Oleyl erucate, Brij (R) 35, Tween (R) 80, Tego Care (R) 450 and Poloxamer (R) 407 were used as the liquid lipid and surfactants for optimization of formulations by design of experiments approach. Thus, oil, surfactant and water contents of nanoemulsions were defined by determination of their droplet size and droplet size distribution by dynamic light scattering method. Formulations were screened by scanning electron microscopy. Drug payload and release properties of the formulations were investigated. Analytical quantification method of EP was validated by high performance liquid chromatograpy. Nanoemulsions having average droplet size between 150.6 nm and 205.8 nm were gained with homogenous droplet size distribution and high entrapment efficiency (84.47-98.51%). Formulations released 44.37-82.87% of EP within 1 h and drug release was completed up to 5-6 h. Thus, drug release characteristics of formulations optimized in this study might introduce benefits for rapid response and maintenance of treatment in hypertension attacks. As a result, design of experiments approach provided accurate and consistent datum with those obtained from experiments on the bench for optimization of formulations.